Halberd Corporation: Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
JACKSON CENTER, PA / ACCESSWIRE / June 1, 2021 / Halberd Corporation (OTC PINK:HALB) announced the filing of a U. S. joint provisional patent application titled,
"Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent discloses the use of such a conjugated moiety as a means of detecting the presence and level of the SARS-CoV-2 viral load in a patient.